CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025

GlobeNewswire

Yesterday

BERKELEY HEIGHTS, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 6, 2025, and will host a corporate update conference call at 8:30am Eastern Time.

*Tuesday, May 6*^th @ 8:30am ET
Domestic:	1-844-676-2922
International:	1-412-634-6840
Conference ID:	10198548
Webcast:	Webcast Link

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath^® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.

Investor Contact:

Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2531736800"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531736800\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2531736800?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-29 20:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2531736800","market":"us","top_or_hot":-1,"title":"CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025","media":"GlobeNewswire","content":"<html><body><img hspace=\"5\" src=\"https://s.yimg.com/uu/api/res/1.2/SZ.UAfLspWY6_xGJQ.Q2vQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/51f441ac293f999ee517fc590cd80730\" title=\"CRMD.jpg\" vspace=\"5\"/>\n<p>BERKELEY HEIGHTS, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/CRMD\">CorMedix Inc.</a> (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 6, 2025, and will host a corporate update conference call at 8:30am Eastern Time.</p>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong><em><u>Tuesday, May 6</u></em></strong><sup><strong><em><u>th</u></em></strong></sup><strong><em><u> @ 8:30am ET</u></em></strong><br/></td>\n</tr>\n<tr>\n<td>Domestic:</td>\n<td>1-844-676-2922</td>\n</tr>\n<tr>\n<td>International:</td>\n<td>1-412-634-6840</td>\n</tr>\n<tr>\n<td>Conference ID:</td>\n<td>10198548</td>\n</tr>\n<tr>\n<td>Webcast:</td>\n<td>Webcast Link</td>\n</tr>\n<tr>\n<td> </td>\n<td> </td>\n</tr>\n</tbody>\n</table>\n<p><strong>About CorMedix</strong></p>\n<p>CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath<sup>®</sup> (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.</p>\n<p><strong>Investor Contact:</strong></p>\n<p>Dan Ferry<br/>Managing Director<br/>LifeSci Advisors<br/>daniel@lifesciadvisors.com <br/>(617) 430-7576<br/><br/><br/><br/></p>\n<br/></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-29 20:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/cormedix-inc-report-first-quarter-123000210.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BERKELEY HEIGHTS, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening...</p>\n\n<a href=\"https://finance.yahoo.com/news/cormedix-inc-report-first-quarter-123000210.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRMD","symbol_name":"CorMedix Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/cormedix-inc-report-first-quarter-123000210.html","article_id":"2531736800","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531736800","pubTimestamp":1745929800,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"BERKELEY HEIGHTS, N.J., April 29, 2025  -- CorMedix Inc. , a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 6, 2025, and will host a corporate update conference call at 8:30am Eastern Time.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRMD":"CorMedix Inc.","BK4007":"制药"},"translate_title":"CorMedix Inc.将于2025年5月6日报告2025年第一季度财务业绩并提供公司更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRMD":1},"content_text":"BERKELEY HEIGHTS, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 6, 2025, and will host a corporate update conference call at 8:30am Eastern Time.\n\n\n\nTuesday, May 6th @ 8:30am ET\n\n\nDomestic:\n1-844-676-2922\n\n\nInternational:\n1-412-634-6840\n\n\nConference ID:\n10198548\n\n\nWebcast:\nWebcast Link\n\n\n \n \n\n\n\nAbout CorMedix\nCorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.\nInvestor Contact:\nDan FerryManaging DirectorLifeSci Advisorsdaniel@lifesciadvisors.com (617) 430-7576","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}